Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003

Increased national disease awareness benefited in vitro diagnostics developers in 2003 as new U.S. testing guidelines and the SARS pandemic combined with recovery in the broader economic market to help fuel growth